MEK162

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

BRAF or NRAS Mutant Metastatic Melanoma

Conditions

BRAF or NRAS Mutant Metastatic Melanoma

Trial Timeline

Mar 24, 2011 → Feb 6, 2023

NCT ID

NCT01320085

About MEK162

MEK162 is a phase 2 stage product being developed by Pfizer for BRAF or NRAS Mutant Metastatic Melanoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01320085. Target conditions include BRAF or NRAS Mutant Metastatic Melanoma.

What happened to similar drugs?

0 of 2 similar drugs in BRAF or NRAS Mutant Metastatic Melanoma were approved

Approved (0) Terminated (1) Active (1)

🔄Encorafenib + Binimetinib + Cetuximab + Irinotecan + Folinic Acid + 5-FluorouracilOno PharmaceuticalPhase 3

❌Cobimetinib + Atezolizumab + PembrolizumabRochePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02050815	Phase 1	Terminated	Mar 1, 2014	Aug 26, 2016	Hepatic Impairment
NCT01885195	Phase 2	Completed	Oct 10, 2013	Apr 11, 2017	Solid Tumor and Hematologic Malignancies
NCT01556568	Phase 2	Withdrawn	Feb 1, 2012	—	Cardiomegaly
NCT01469130	Phase 1	Completed	Nov 1, 2011	Feb 1, 2018	Advanced Solid Tumor
NCT01320085	Phase 2	Completed	Mar 24, 2011	Feb 6, 2023	BRAF or NRAS Mutant Metastatic Melanoma

Competing Products

13 competing products in BRAF or NRAS Mutant Metastatic Melanoma

See all competitors

Product	Company	Stage	Hype Score
PLX3397 + vemurafenib	Daiichi Sankyo	Phase 1	21
TMZ + E7016	Eisai	Phase 2	27
Encorafenib + Binimetinib + Cetuximab + Irinotecan + Folinic Acid + 5-Fluorouracil	Ono Pharmaceutical	Phase 3	40
encorafenib + Binimetinib + Cetuximab	Ono Pharmaceutical	Phase 2	35
Encorafenib + Cetuximab + FOLFIRI	Merck	Phase 2	35
Tafinlar/Mekinist	Novartis	Pre-clinical	33
BKM120 Combined with Vemurafenib (PLX4032)	Novartis	Phase 1/2	32
Dabrafenib + LTT462 + Trametinib + LXH254 + TNO155 + Spartalizumab + Tislelizumab	Novartis	Phase 1	21
Cobimetinib + Atezolizumab + Pembrolizumab	Roche	Phase 3	32
LGX818 + MEK162 + LEE011	Pfizer	Phase 1/2	32
Encorafenib + Binimetinib + cemiplimab+fianlimab	Regeneron Pharmaceuticals	Phase 2	42
Plixorafenib + Cobicistat 150 MG [Tybost]	Brain Biotech	Phase 1	26
Dabrafenib + Trametinib + Hydroxychloroquine	Brain Biotech	Phase 1/2	26